Evidence-based Lifestyle Interventions for the Delay of Cognitive Decline Among Older Singaporeans
NCT06661486, Not applicable, Active not recruiting, National University of Singapore
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evidence-based Lifestyle Interventions for the Delay of Cognitive Decline Among Older Singaporeans | ClinicalTrials.gov |
| NCT number | NCT06661486 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | National University of Singapore | ClinicalTrials.gov |
| Conditions | Non Demented | ClinicalTrials.gov |
| Interventions | Uniformed intervention group, Individualised intervention group | ClinicalTrials.gov |
| First posted | 2024-10-28 | ClinicalTrials.gov |
| Last updated | 2026-08-31 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Standard Neuropsychological Tests of Information Processing Speed | Cognitive assessment will be conducted at three timepoints within 2 years period, baseline, 12 months and 24 months | The primary outcome of the trial is the processing speed, measured using the average of domain Z score derived from raw scores of three tests including the symbol digit modality test, colour trial test (Condition A) and Stroop test (Condition 2). The average of Z scores standardised to the baseline mean and standard deviation of trial participants, with higher scores representing better processing speed. | ClinicalTrials.gov |
| Secondary | Biological Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Secondary outcome measures include biological outcome: i. epigenetic age (DNA methylation) | ClinicalTrials.gov |
| Secondary | Biological Outcome | All of the outcome meausures will be measured at three timepoints including baseline, 12 months and 24 months | Secondary outcome measures include biological outcome: ii. plasma-based markers of inflammation | ClinicalTrials.gov |
| Secondary | Quality of life Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Health-related Quality-of-life questionnaires: EuroQol-5 Dimension 5 Levels EQ-5D-5L. The result will not derive a summary score, "1" represents no problem and "5" represents extreme. | ClinicalTrials.gov |
| Secondary | Quality of life Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Quality-of-life questionnaires: ICEpop CAPability measure for Older adults ICECAP-O. The result will not derive a summary score, "1" represents no ability, "4" represents no problem. | ClinicalTrials.gov |
| Secondary | Social Support Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Duke Social Support Index DSSI-11. The sum of 11 items, a higher score represents better social support. Minimum 11, maximum 33. | ClinicalTrials.gov |
| Secondary | Capability-related Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Capability-related questionnaires: Basic Activities of Daily Living ADL The sum of 10 items. A higher score represents better capability: minimum 0, maximum 20. | ClinicalTrials.gov |
| Secondary | Capability-related Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Capability-related questionnaires: Instrumental Activities of Daily Living IADL.The sum of 8 items, a higher score represents better capability: minimum 0, maximum 8. | ClinicalTrials.gov |
| Secondary | Sleep Quality Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Pittsburgh Sleep Quality Index PSQI. A sum of 7 components, with global scores ranging from 0-21, a higher score represents worse sleep quality. | ClinicalTrials.gov |
| Secondary | Mental Health Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Mental health outcome: Geriatric Depression Scale GDS. A sum score of 15 items, a lower score represents lesser depression: Minimum 0, maximum 15. | ClinicalTrials.gov |
| Secondary | Mental Health Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Mental health outcome: Geriatric Anxiety Inventory GAI. A sum score of 20 items, a lower score represents lesser anxiety: Minimum 0, maximum 20. | ClinicalTrials.gov |
| Secondary | Mental Health Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Mental health outcome: Perceived Stress Scale PSS. A sum score of 10 items, a lower score represents lower stress: Minimum 0, maximum 40. | ClinicalTrials.gov |
| Secondary | Cognitive Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Mini-Mental State Examination (MMSE), total score of 30 items, a higher score better cognitive: Minimum 0, maximum 30. | ClinicalTrials.gov |
| Secondary | Cognitive Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Clinical Dementia Rating (CDR), a higher score higher impairment in cognitive function, high risk in dementia, global score ranged from 0 to 3. | ClinicalTrials.gov |
| Secondary | Neurocognitive Tests Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Neuropsychological tests: Rey Auditory Verbal Learning Test (RAVLT). Different summary scores are derived from raw RAVLT scores: Minumum 0, maximum 15. A higher score better verbal memory. | ClinicalTrials.gov |
| Secondary | Neurocognitive Tests Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Neuropsychological tests: Digit Span Task. Higher scores represent better cognitive performance. | ClinicalTrials.gov |
| Secondary | Neurocognitive Tests Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Neuropsychological test: Block Design (BD). Higher scores represent better cognitive performance: Minimum 0, Maximum 68. | ClinicalTrials.gov |
| Secondary | Neurocognitive Tests Outcome | All of the outcome measures will be measured at three timepoints including baseline, 12 months and 24 months | Neuropsychological test: Boston Naming Test (BNT) . Higher scores represent better cognitive performance: Minimum 0, maximum 30. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)